Michael L. Meyers
Director/Board Member chez NUVALENT, INC.
Fortune : - $ au 31/03/2024
Profil
Michael L.
Meyers is currently an Independent Director at Nuvalent, Inc., a Vice President at Janssen Research & Development LLC, and the Chief Medical Officer at Flare Therapeutics, Inc. He previously held positions as a Vice President-GU Oncology & Compound at Johnson & Johnson, the Chief Medical Officer & Senior Vice President at Syndax Pharmaceuticals, Inc., a Member at Memorial Sloan Kettering Cancer Center, and a Vice President-Oncology Scientific Innovation at Johnson & Johnson Innovation LLC.
Dr. Meyers obtained a doctorate degree from Albert Einstein College of Medicine, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NUVALENT, INC. CLASS A
-.--% | 15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Michael L. Meyers
| Sociétés | Poste | Début |
|---|---|---|
| NUVALENT, INC. | Director/Board Member | 04/10/2022 |
Janssen Research & Development LLC
 Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a private company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Corporate Officer/Principal | - |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Chief Tech/Sci/R&D Officer | 01/03/2023 |
Anciens postes connus de Michael L. Meyers
| Sociétés | Poste | Fin |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/03/2022 |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Johnson & Johnson Innovation LLC
 Johnson & Johnson Innovation LLC Medical/Nursing ServicesHealth Services Part of Johnson & Johnson, Johnson & Johnson Innovation LLC focuses on accelerating innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's healthcare businesses. The private company is based in South San Francisco, CA. Johnson & Johnson Innovation provides scientists, entrepreneurs, and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device, and consumer companies of Johnson & Johnson. The company connects with innovators through its regional innovation centers, Johnson & Johnson Innovation - JLABS, JJDC, Inc., and its business development teams to create customized deals and novel collaborations that speed up the development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools, and resources needed to help life science startups thrive, all with no strings attached. Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. | Corporate Officer/Principal | - |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - |
Formation de Michael L. Meyers
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| NUVALENT, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Health Services |
Janssen Research & Development LLC
Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a private company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Commercial Services |
Johnson & Johnson Innovation LLC
Johnson & Johnson Innovation LLC Medical/Nursing ServicesHealth Services Part of Johnson & Johnson, Johnson & Johnson Innovation LLC focuses on accelerating innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's healthcare businesses. The private company is based in South San Francisco, CA. Johnson & Johnson Innovation provides scientists, entrepreneurs, and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device, and consumer companies of Johnson & Johnson. The company connects with innovators through its regional innovation centers, Johnson & Johnson Innovation - JLABS, JJDC, Inc., and its business development teams to create customized deals and novel collaborations that speed up the development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools, and resources needed to help life science startups thrive, all with no strings attached. Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices. | Health Services |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Health Technology |
